bowel disease (IBD) and rheumatoid arthritis (RA) (Abdul Sultan et al., 2016; Langen, Chakravarty, Liaquat, El-Sayed, & Druzin, 2014; Lin, Chen, Lin, & Chen, 2010; Shand, Chen, Selby, Solomon, & Roberts, 2016) . Furthermore, many of the same hypoxia-related cytokines and growth factors associated with IH development have been implicated in the disease pathogenesis of these chronic inflammatory conditions (Gaber, Dziurla, Tripmacher, Burmester, & Buttgereit, 2005; Konisti, Kiriakidis, & Paleolog, 2012; Scaldaferri et al., 2009; Xu & Dong, 2016) .
This study was undertaken to analyze the risk of maternal autoimmune disease and associated treatments on IHs to provide more insight into the role of maternal inflammation in IH pathogenesis.
To our knowledge, this is the first study to examine the potential association between the presence of autoimmune disease and this particular fetal outcome.
| MATERIALS AND METHODS

| Source of the sample
Data for this analysis were obtained from the Organization of Teratology Information Specialists (OTIS) Autoimmune Disease in Pregnancy
Project, a prospective cohort study of pregnancy outcomes among women in the United States and Canada. Participants in the study were recruited from pregnant callers to OTIS counseling services throughout the United States and Canada who initiated contact with an OTIS service with questions about any exposure in pregnancy, as well as direct marketing to consumers through social media and the OTIS MotherToBaby study website. Participants were also recruited through direct marketing to rheumatologists, gastroenterologists, dermatologists, neurologists, obstetricians, nurses, and other health care professionals through mail, professional meetings, and the website. Women were eligible for the overall cohort study if they enrolled prior to 19 completed weeks' gestation, and had not enrolled in this study with a previous pregnancy. Pregnant women who enrolled in the study between 2004 and 2013, and delivered at least one live born infant were eligible for the analysis. To increase the reliability and validity of the diagnosis of IH, the sample was further restricted to the subset of infants that received a blinded physical examination by a study dysmorphologist for the presence or absence of major and minor physical features including IH.
The protocol was approved by the institutional review board at the University of California, San Diego. All women in the study initially provided oral consent for participation, and subsequently provided written consent for the dysmorphology exam.
| Study design and data collection
Women who consented to participate were interviewed by telephone two to three times during pregnancy using a standard questionnaire about their medical history, prescription and non-prescription medication exposures during pregnancy, history of previous pregnancies, family medical history, pre-pregnancy body mass index, and socio-economic and demographic characteristics of the woman and her partner. Exposure history included start and stop dates of each prescription and over-the-counter medication, as well as indications, dosage changes, and frequencies, use of caffeine, dietary supplements, occupational exposures, infections, prenatal testing or other medical procedures, and use of recreational drugs, tobacco, and alcohol.
Birth outcomes were obtained using a standard interview form completed by telephone shortly after delivery. Women were asked about exposure information through the end of pregnancy, the presence or absence of major structural defects, gestational age at delivery, mode of delivery, length and type of hospital stay, maternal or newborn complications, maternal weight gain, and infant birth weight, length, and head circumference.
Medical records from the prenatal care provider, delivery hospital, any specialty providers that managed the woman's care in pregnancy, and the pediatrician were collected and data abstracted for additional exposure and outcome information, including validation of maternal self-report of autoimmune disease diagnosis. In addition, the infant's physician was asked to return a form reporting postnatal growth measures and the presence or absence of any major structural defect noted up to that point.
Live-born infants underwent a blinded physical examination by one of six study dysmorphologists who traveled to examine the infants in their home typically in the first year of life. These evaluations were completed for both major and minor structural anomalies, including IH.
If one or more IH(s) were identified on the dysmorphology exam, the examiner frequently noted the size and location of the IH. Minor anomalies were defined as structural defects with no cosmetic or functional importance that are known to occur in <4% of the general population (Marden, Smith, & McDonald, 1964) . Infants who received a dysmorphologic examination were evaluated using a standard checklist itemizing 132 such minor anomalies (Chambers et al., 2001 ).
With parental consent, photographs were taken of each infant to aid in addressing possible issues of interrater reliability among multiple examiners. The examiner in each case was blinded with regards to the medication exposure and autoimmune disease status of the mother. Women who were enrolled in the study who met criteria for inclusion in this analysis and had no history of any of the aforementioned autoimmune diseases were selected as a comparison cohort.
Medication treatments for autoimmune diseases were grouped by class and defined as treatment at any dose for any length of time in pregnancy. The specific classes of medications considered included biologics, non-biologic disease modifying anti-rheumatic drugs (DMARDs), and oral glucocorticosteroids.
Disease activity for autoimmune subjects was documented at initial intake and 32 weeks' gestation using the following standardized questionnaires: Health Assessment Questionnaire-Disability Index SMITH ET AL.
| 571 (HAQ-DI) for rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis, and the Short Inflammatory Bowel Disease Questionnaire (SIBDQ) for Crohn's and UC subjects (Bruce & Fries, 2003; Irvine, Zhou, & Thompson, 1996) . HAQ-DI scores ranged from 0-3, and final calculated values ≤0.5 were categorized as "low" disease activity, and scores >0.5 were categorized as "high" disease activity. While there are no widely validated cutoff values for SIBDQ values, calculated SIBDQ scores ranging from 10-30 were categorized as "high" disease activity, and scores ranging from 31-70 were categorized as "low" disease activity, based upon correlations between SIBDQ scores and disease severity observed in a study by Jowett, Seal, Barton, & Welfare, 2001 .
| Covariates
Baseline covariates considered in the analysis included the following: maternal age in years at the time of conception, parity and gravidity at the time of conception, pre-pregnancy body mass index (BMI), maternal race, maternal Hispanic ethnicity, education level, and household income. Outcomes considered as covariates in the analysis included the following: preeclampsia, preterm delivery, infant sex, birth weight, and whether the infant was a product of multiple gestation (i.e., a twin or higher order multiple). Multiple gestation was further defined as a pregnancy with more than one fetus identified during prenatal care, regardless of whether all fetuses resulted in live births. Preterm delivery was defined as delivery at less than 37 completed weeks' gestation regardless of mode of delivery or indication; low birth weight (LBW) was defined as less than 2,500 g regardless of sex of the infant or gestational age at delivery, and very low birth weight (VLBW) was defined as less than 1,500 g.
| Statistical analyses
Maternal characteristics were compared by presence or absence of IH in the infant using two-tailed univariate comparisons with Student's t-test for continuous variables and Fisher's Exact Test or χ 2 tests for categorical variables, depending on the cell size. Next, the odds ratios of IH were estimated by maternal autoimmune status. The sample was further limited to autoimmune cases, and the odds of IH were then calculated for disease activity. Lastly, odds of IH were calculated for categories of medication use (biologic medication as compared to nonbiologic medication or no medication use, biologic medication alone as compared to DMARD alone, and DMARD treatment compared to no medication use).
Pregnancies that ended with more than one live-born infant were counted as separate events with respect to IH. Numbers of IH events were too limited to perform multivariable analysis or analysis based on size of the tumor; however, the distribution of IH by size was described within categories of infant sex, medication use, and maternal autoimmune disease. Size of IH was classified into three groups:
≤1 × 1 cm, >1 × 1 cm to <3 × 3 cm, and ≥3 × 3 cm. If more than one hemangioma was present, the larger lesion was classified according to size. A lesion that was considered large or of medical significance was classified as a major malformation using the US Centers for Disease
Control and Prevention criteria. Despite IH not being typically present at birth, the term "birth prevalence" was used when referencing these malformations instead of "incidence" as part of standard practice, given the possibility that many of these anomalies may be lost prior to pregnancy recognition. Of the 59 infants with IH, 46 had the lesion(s) size documented.
Five had a clinically significant lesion that was at least 3 cm in diameter.
Four of these five infants were female, all five infants were born to mothers in the autoimmune group (2 RA, 1 RA, and CD, 1 CD alone, 1
PsA), and all five mothers were taking a biologic medication during pregnancy (Table 5) . Of note, four of the five mothers of an infant with large IH took a biologic medication through the third trimester of their pregnancy (data not shown). PCVMCCs that have embolized to the developing fetus during the first trimester (Itinteang et al., 2011) . The subsequent cellular proliferation of IHs during early infancy has been linked to maternal events associated with hypoxic stress as well as hypoxia-induced factors in the infant (Smith, Friedlander, Guma, Kavanaugh, & Chambers, 2017) . The HIF-1a cascade and its downstream targets have been repeatedly implicated in IH development (de Jong et al., 2016) . Glucose transporter-1 (GLUT-1), a marker of glucose metabolism and a downstream target of HIF-1a, has been shown to be universally expressed in IH tissue (de Jong et al., 2016; North et al., 2001) . In a recent study by El-Raggal et al. (2017) vascular endothelial growth factor (VEGF), another product of the HIF-1a cascade, was observed in significantly higher levels in the sera of IH patients than those with other vascular malformations (2017).
Interestingly, tissue hypoxia may also have an important impact on inflammatory signaling in IBD (Biddlestone, Bandarra, & Rocha, 2015; Cummins, Keogh, Crean, & Taylor, 2016) . One study by Xu and Dong (2016) found increased amounts of HIF-1a in the sera of UC patients correlating with disease activity (2016). GLUT-1, the downstream target of HIF-1a that is strongly associated with IH, has been detected in the colonic epithelia of patients with UC (Fogt et al., 2001 ). Furthermore, VEGF may also play an important role in the angiogenesis and intestinal inflammation seen in IBD (Scaldaferri et al., 2009 ). Hypoxia-induced factors are thus an intrinsic component of both IH pathogenesis and UC inflammatory signaling.
In this study, maternal biologic use was not significantly associated with development of IH in the infant. Overall the frequency of IH was higher in infants born to mothers taking biologic therapy at any time in pregnancy than seen in the comparison groups, but none of the comparisons achieved statistical significance. Our study is not the first to assess risk of maternal use of biologic medications on potential fetal birth defects. A prospective cohort study by Weber-Schoendorfer et al. (2015) analyzed pregnancy outcomes in 495 tumor necrosis factor inhibitor-exposed pregnancies, about half of whom had IBD, and identified four of the twenty one major defects seen as IHs (2015).
These included two of nine major defects in an adalimumab-exposed group, and two of seven major defects in an infliximab-exposed group, the former two cases indicated for AS and the latter two indicated for Crohn's and UC. While we did not conclude in our study that any maternal autoimmune disease treatment or the overall presence of autoimmune disease itself was associated with IH, we did note a clustering of larger IH in infants born to mothers who had autoimmune Disease activity measures were included in this study given the potential for confounding, as maternal disease and disease activity have the potential to directly affect choice of medication in the mother.
Similarly, maternal disease activity may also impact the incidence of preterm delivery, LBW infants, and other covariates analyzed in this Infantile hemangioma size (cm) | 575 study, as higher disease activity has been shown to correlate with these perinatal outcomes (Atta et al., 2016; Kammerlander et al., 2017) . In our study, no association was identified between the presence of IH and maternal disease activity measures collected at intake, although a borderline protective effect was seen with HAQ-DI at 32 weeks. The latter finding is based on an unadjusted analysis with small numbers, however, and may have been influenced by the fact that higher disease activity may be seen in patients not taking diseasemodifying medications. Regardless, more research is necessary to tease out the potential relationship between disease activity on IH.
The relatively small number of infants with IH was a limitation of this study, limiting statistical power to detect more modest differences between groups, to allow for classification of medication use by gestational timing and dose, or to allow for multivariable adjustment.
No adjustment for multiple testing was performed, and given the large number of comparisons, it is possible that some of our findings may have been due to chance alone. Another limitation of the disease activity analysis is that all measures were collected during pregnancy and not necessarily prior to initiation of treatment, so the temporality between disease severity and treatment was not evaluated. Furthermore, disease activity measures were not available for those in the sample with psoriasis alone.
A strength of the study was the standardized and specialized blinded physical examination conducted for all infants. This ensured that the IH(s) that were still present in the infant would be uniformly detected, and that the exact sizes and locations of the IH(s) could be noted, which is pertinent to clinical implications. Some of the IH lesions (13 out of 59) did not have specific size or location noted by the examiner. However, none of these lesions were considered major malformations and thus were presumably of smaller size and with less clinical significance. Lastly, despite similar timing of dysmorphological evaluations performed in the autoimmune and comparison cohorts, it is possible that some infants with an IH were not detected, as the lesion may have already regressed by the time the child was evaluated.
The results of this study add to the limited knowledge regarding birth outcomes and presence of IHs in the autoimmune population.
Further and larger studies would be warranted to continue investigating the potential association between maternal presence of autoimmune disease, particularly UC, and infant development of IH.
